EUVIMEDEUVIMED entdecken
Crossref

Inhibition of cyclooxygenase and EP3 receptor improved long term potentiation in a rat organotypic hippocampal model of repeated blast traumatic brain injury

Nevin Varghese, Barclay Morrison

Neurochemistry International · 2023-02 · 163 · 105472

DOI: 10.1016/j.neuint.2022.105472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurochemistry International, 2023-02. Verfasst von Nevin Varghese und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Columbia University, 1210 Amsterdam Avenue, New York, NY, 10027, USA. Electronic address: nv2295@columbia.edu. Hauptthemen laut MEDLINE: Blast Injuries, Brain Injuries, Traumatic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: The Paul G Allen Frontiers Group, DEVCOM Army Research Laboratory, US Army Combat Capabilities Development Command.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blast-induced traumatic brain injury (bTBI) is a health concern in military service members who are exposed to multiple blasts throughout their training and deployment. Our group has previously reported decreased long term potentiation (LTP) following repeated bTBI in a rat organotypic hippocampal slice culture (OHSC) model. In this study, we investigated changes in inflammatory markers like cyclooxygenase (COX) and tested the efficacy of COX or prostaglandin EP3 receptor (EP3R) inhibitors in attenuating LTP deficits. Expression of COX-2 was increased 48 h following repeated injury, whereas COX-1 expression was unchanged. EP3R expression was upregulated, and cyclic adenosine monophosphate (cAMP) concentration was decreased after repeated blast exposure. Post-traumatic LTP deficits improved after treatment with a COX-1 specific inhibitor, SC-560, a COX-2 specific inhibitor, rofecoxib, a pan-COX inhibitor, ibuprofen, or an EP3R inhibitor, L-798,106. Delayed treatment with ibuprofen and L-798,106 also prevented LTP deficits. These findings suggest that bTBI induced neuroinflammation may be responsible for some functional deficits that we have observed in injured OHSCs. Additionally, COX and EP3R inhibition may be viable therapeutic strategies to reduce neurophysiological deficits after repeated bTBI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blast InjuriesBrain Injuries, TraumaticRatsAnimalsCyclooxygenase 2Long-Term PotentiationIbuprofenHippocampus

Stichwörter der Autor:innen

COX-inhibitionEP3 receptor inhibitionElectrophysiologyHippocampusLong term potentiationRepeated blast traumatic brain injury

Substanzen

Cyclooxygenase 2Ibuprofen

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Columbia University, 1210 Amsterdam Avenue, New York, NY, 10027, USA. Electronic address: nv2295@columbia.edu.
  • Department of Biomedical Engineering, Columbia University, 1210 Amsterdam Avenue, New York, NY, 10027, USA. Electronic address: bm2119@columbia.edu.

Förderung

  • The Paul G Allen Frontiers Group
  • DEVCOM Army Research Laboratory
  • US Army Combat Capabilities Development Command

Zitieren

APA

Varghese, N., & Morrison, B. (2023). Inhibition of cyclooxygenase and EP3 receptor improved long term potentiation in a rat organotypic hippocampal model of repeated blast traumatic brain injury. Neurochemistry International, 163, 105472. https://doi.org/10.1016/j.neuint.2022.105472

Vancouver

Varghese N, Morrison B. Inhibition of cyclooxygenase and EP3 receptor improved long term potentiation in a rat organotypic hippocampal model of repeated blast traumatic brain injury. Neurochemistry International. 2023;163:105472. doi:10.1016/j.neuint.2022.105472

BibTeX
@article{Varghese2023,
  author = {Varghese, Nevin and Morrison, Barclay},
  title = {Inhibition of cyclooxygenase and EP3 receptor improved long term potentiation in a rat organotypic hippocampal model of repeated blast traumatic brain injury},
  journal = {Neurochemistry International},
  year = {2023},
  volume = {163},
  pages = {105472},
  doi = {10.1016/j.neuint.2022.105472}
}
Kostenlos starten →